Charles River Laboratories International, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Invesco Ltd. has disclosed beneficial ownership of 6.2% of Charles River Laboratories International Inc.'s common stock as of June 30, 2026.
NYSE
FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, disclosing beneficial ownership of 4,239,751.47 shares, representing 8.8% of Charles River Laboratories International, Inc.'s common stock as of June 30, 2026.
NYSE
Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of Charles River Laboratories International Inc. common stock as of March 31, 2026.
NYSE
FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Charles River Laboratories International Inc. common stock as of March 31, 2026.
NYSE
Vanguard Capital Management has reported a beneficial ownership of 7.38% in Charles River Laboratories International Inc., holding 3,634,376 shares.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Charles River Laboratories International Inc. following an internal realignment.
NYSE
Invesco Ltd. has reported a 5.5% beneficial ownership stake in Charles River Laboratories International Inc. common stock.
NYSE
Wellington Management Group and its affiliates reported a 3.55% beneficial ownership stake in Charles River Laboratories International, Inc. common stock as of December 31, 2025.
NYSE
Nomura Holdings Inc. has reported a 1.6% beneficial ownership stake in Charles River Laboratories International, Inc. as of September 30, 2025.
NYSE
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 6.48% beneficial ownership in Charles River Laboratories International, Inc. common stock.
NYSE
Nomura Holdings Inc. has disclosed a passive 5.4% beneficial ownership stake in Charles River Laboratories International, Inc., totaling 2,681,669 shares.
NYSE
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% of Charles River Laboratories International, Inc. common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Charles River Laboratories International Inc. as of March 31, 2025.